For foreign patent attorneys entering India through the PCT route, Section 8 of the Patents Act, 1970 is often underestimated. It is frequently viewed as a procedural filing requirement to be completed at the time of national phase entry. In practice, it is a continuing statutory obligation that can influence examination, opposition, and even post-grant validity. Non-compliance is routinely raised in First Examination Reports and is regularly invoked in contentious proceedings.
Section 8(1) requires an applicant to furnish details of corresponding foreign applications relating to the same or substantially the same invention. This disclosure is typically made through Form 3 at the time of filing or within the prescribed period. However, the obligation does not end there. Section 8(2) empowers the Controller to require submission of additional details concerning the processing of such foreign applications, including examination reports and the status of claims. The statutory language makes it clear that this is a continuing responsibility throughout prosecution.
In the context of PCT national phase applications, a common misconception is that the international search report and written opinion available in the public domain sufficiently address disclosure concerns. That assumption is misplaced. Once the application enters India, the applicant must independently comply with Section 8 requirements. If there are parallel national phase entries, continuation filings, divisionals, or significant claim amendments in other jurisdictions, these developments may fall within the scope of disclosure. Failure to update the record when required can trigger objections and, in adversarial settings, become a strategic ground of challenge.
The phrase “same or substantially the same invention” is interpreted broadly. It can extend to parent applications, divisionals, continuations, and related family members depending on the degree of claim overlap. From a risk management perspective, incomplete disclosure presents greater exposure than comprehensive disclosure. At the same time, indiscriminate reporting without monitoring consistency across jurisdictions can create complications if positions taken abroad differ from those advanced in India. The disclosure must therefore be accurate, timely, and coordinated with global prosecution strategy.
Section 8 has been used as a ground in both pre-grant and post-grant opposition proceedings, as well as in revocation actions. Although judicial interpretation has evolved and courts have emphasized materiality rather than automatic invalidation, Section 8 remains a litigation-sensitive provision. Opponents routinely review foreign prosecution histories and compare them with Indian disclosures. In high-value sectors such as pharmaceuticals, chemicals, and technology-driven portfolios, allegations of incomplete or inconsistent disclosure are frequently raised alongside novelty and inventive step challenges.
In practical terms, exposure often arises not from deliberate omission but from portfolio complexity. Large patent families with multiple continuations, divisionals, and jurisdiction-specific claim amendments increase the likelihood of gaps in disclosure. Office actions from major jurisdictions that are not furnished when requested, or inconsistencies in claim scope that are not reconciled in the Indian record, can become focal points during opposition. Coordination failures between global prosecution teams and Indian counsel are a common source of difficulty.
During examination, Controllers may raise objections where Form 3 appears outdated or inconsistent with publicly available information. Requests under Section 8(2) must be handled with care and within the stipulated timelines. Delayed or incomplete responses can weaken the applicant’s position and extend prosecution unnecessarily. India should not be treated as a passive jurisdiction within a large global portfolio. Disclosure management requires active monitoring throughout the lifecycle of the application.
At the national phase entry stage, it is prudent to conduct a structured review of the global filing landscape for the invention. This includes identifying related family members, understanding the status of foreign prosecution, and anticipating potential future filings such as divisionals. Establishing an internal mechanism to track developments in key jurisdictions and update Indian disclosures accordingly reduces procedural vulnerability. In commercially significant matters, disciplined Section 8 compliance is as important as substantive patentability arguments.
Section 8 is not a clerical requirement. It is a statutory obligation with procedural and strategic consequences. For PCT national phase applications entering India, particularly those forming part of complex international portfolios, proactive disclosure management is essential to reduce examination delays and opposition risk.
For coordinated Section 8 compliance strategy and prosecution support in India PCT national phase matters, please contact us at https://origiin.com/contact-us/. To understand the India national phase procedure and compliance framework in detail, please visit https://origiin.com/pct-national-phase-entry-india/.
